This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zéphir, H Articles by Vermersch, P Search for Related Content PubMed PubMed Citation Articles by Zéphir, H Articles by Vermersch, P Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE METHYLPREDNISOLONE Social Bookmarking                   What's this?

One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis

Department of Neurology, Hôpital Roger Salengro, University of Lille II and CHR, 59047 Lille cedex, France, helenez{at}nomade.fr

J de Seze

Department of Neurology, Hôpital Roger Salengro, University of Lille II and CHR, 59047 Lille cedex, France

K Dujardin

Department of Psychology, University of Lille III, France

G Dubois

Department of Psychology, University of Lille III, France

M Cabaret

Department of Neurology, Hôpital Roger Salengro, University of Lille II and CHR, 59047 Lille cedex, France

S Bouillaguet

Department of Neurology, Hôpital Roger Salengro, University of Lille II and CHR, 59047 Lille cedex, France

D Ferriby

Department of Neurology, Hôpital Roger Salengro, University of Lille II and CHR, 59047 Lille cedex, France

T Stojkovic

Department of Neurology, Hôpital Roger Salengro, University of Lille II and CHR, 59047 Lille cedex, France

P Vermersch

Department of Neurology, Hôpital Roger Salengro, University of Lille II and CHR, 59047 Lille cedex, France

We conducted an evaluation of changes in cognition in progressive multiple sclerosis (MS) patients receiving monthly intravenously pulse of cyclophosphamide (700 mg/m²) with methylprednisolone (1 g). Twenty-eight consecutive progressive MS patients (10 primary progressive, 18 secondary progressive MS) were evaluated before and after six and 12 months of treatment. The WAIS-R score, memory and executive functions were evaluated. Under treatment we found a significant improvement in global cognitive efficiency, encoding abilities, planning abilities and inhibition after six and 12 months. However, mechanisms of action of the positive effect of these anti-inflammatory and immunosuppressive treatments on cognition remain unclear.

Key Words: cognitive function • cyclophosphamide • methylprednisolone • progressive multiple sclerosis

Multiple Sclerosis, Vol. 11, No. 3, 360-363 (2005)
DOI: 10.1191/1352458505ms1172sr


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. S. Haussleiter, M. Brune, and G. Juckel Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 13 - 29. [Abstract] [PDF]

				M. Summers, L. Fisniku, V. Anderson, D. Miller, L. Cipolotti, and M. Ron Cognitive impairment in relapsing--remitting multiple sclerosis can be predicted by imaging performed several years earlier Multiple Sclerosis, March 1, 2008; 14(2): 197 - 204. [Abstract] [PDF]